Sellas Life Sciences Stock Jumps on Trial Results Timeline

By Liliana Orozco | November 13, 2026, 10:19 AM

Sellas Life Sciences Group Inc (NASDAQ:SLS) stock is up 7% to trade at $8.59 after the biotech company announced that results from its closely watched leukemia trial are expected later this month. The CEO also highlighted the treatment's potential to be a "transformative" immunotherapy if the results prove successful.

The shares are rebounding off $8 after a week of choppy trading near five-month lows. SLS has shed 46% since its June 30 record high of $15.88 but still sports a 438% year-over-year gain.

Short sellers could fuel further gains, with 26.87% of the stock's total available float now sold short. It would take short sellers roughly eight days for shorts to buy back their bearish bets.

Options bears are more active than usual. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), SLS' 50-day put/call volume ratio of 0.73 ranks in the 80th percentile of its annual range.

Mentioned In This Article

SLS

-0.19%

SELLAS Life Sciences Group Inc

Latest News

2 hours	Sellas Life Sciences Stock Jumps on Trial Results Timeline SLS Schaeffer's Research
6 hours	Futures Edge Lower As NVDA Fallout Unsettles Tech Stocks SLS, AMAT, CSCO, CADL Stocks In Focus SLS Stocktwits
Nov-12	SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month SLS Stocktwits
Nov-12	SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update SLS GlobeNewswire
Nov-10	SLS Stock Rises After-Hours: State Street Reveals Over 5% Stake And One Fund Manager Boosted Holdings By Nearly 1,000% SLS Stocktwits
Nov-10	SLS Stock Rises Overnight: Retail Bets The Regal Wait Is Almost Over Heres What Wall Street Expects From Earnings SLS Stocktwits
Nov-09	Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA Geode Adds More SLS Stocktwits
Nov-04	SLS Stock Rises Overnight Despite Citis 64% Stake Cut Retail Bulls Say SLS009 Alone Could Outvalue Sellas SLS SLS -13.79% Stocktwits
Nov-04	Sellas To Present SLS009 Data At American Society of Hematology Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4 SLS Stocktwits
Nov-04	SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 SLS GlobeNewswire
Nov-03	SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets SLS Stocktwits
Nov-02	SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data Fresh Filings Show Q3 Stake Hikes Of Over 400% SLS -11.67% Stocktwits
Nov-02	SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus SLS -11.67% Stocktwits
Oct-30	SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3 SLS Stocktwits
Oct-28	SLS Stocks Big AML Trial Milestone Sparks A Selloff Whats Fueling Retails Extremely Bullish Bets? SLS -14.71% Stocktwits

Sellas Life Sciences Stock Jumps on Trial Results Timeline

Mentioned In This Article

Latest News

Upgrade your Finviz experience